| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 5.99% | 58.95% | 67.32% | 22.21% | 45.43% | 34.35% | 53.02% | 50.31% | 63.18% | 61.57% | 66.67% | 54.19% |
| Operating Margin | -896.55% | -140.03% | -150.50% | -666.49% | -335.28% | -757.46% | -971.89% | -1353.14% | -1293.31% | -1011.35% | -968.71% | -596.55% |
| EBITDA Margin | -861.42% | -139.99% | -150.46% | -666.36% | -335.16% | -757.14% | -971.13% | -1351.26% | -1291.21% | -1008.30% | -962.59% | -592.12% |
| Net Margin | -712.30% | -144.84% | -162.55% | -724.47% | -842.60% | -694.22% | -1093.21% | -1306.29% | -2077.41% | -1236.24% | -1961.90% | -1303.94% |
| Current Ratio | 1.09 | 1.22 | 2.64 | 2.42 | 4.38 | 2.75 | 4.49 | 1.92 | 5.67 | 0.39 | 5.98 | 0.03 |
| Quick Ratio | 0.74 | 0.42 | 1.53 | 1.48 | 4.29 | 2.70 | 4.20 | 1.70 | 5.57 | 0.27 | 5.74 | 0.02 |
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — |
| ROE | -54.29% | -590.91% | -93.05% | -168.51% | -226.23% | -180.66% | -429.82% | -897.19% | -136.63% | 113.29% | 1379.90% | 47.13% |
| ROA | -44.22% | -102.09% | -55.60% | -92.67% | -165.65% | -52.56% | -284.58% | -262.91% | -102.06% | -573.08% | -145.44% | -366.11% |
| Asset Turnover | 0.06 | 0.70 | 0.34 | 0.13 | 0.20 | 0.08 | 0.26 | 0.20 | 0.05 | 0.46 | 0.07 | 0.28 |
| Book Value / Share | 53.29 | 2.32 | 2.28 | 2.28 | 0.25 | 0.23 | 0.19 | 0.07 | 0.73 | -0.55 | -0.11 | -36.23 |
ENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at-home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures. In addition, it provides WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally. The company was formerly known as NanoVibronix, Inc. and changed its name to ENvue Medical, Inc. in December 2025. The company was incorporated in 2003 and is based in Tyler, Texas.